NKP-1339 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This NKP-1339 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 11 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether NKP-1339 can convert its Small molecule drug profile and HSPA5 x p38 MAPK biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | NKP-1339 (query alias: NKP-1339) |
|---|---|
| Modality / target | Small molecule drug; HSPA5 x p38 MAPK; HSPA5 inhibitors, p38 MAPK inhibitors |
| Highest global status | Phase 2 |
| Originator | Medical University of Vienna |
| Active developers | Bold Therapeutics, Inc., Hana Pharm Co., Ltd., Seoul National University |
The MCP disease footprint includes Biliary Tract Neoplasms, Colorectal Cancer, Stomach Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07027423 | Phase 1 | Not yet recruiting | 32 | Primary endpoint not disclosed in English source |
| NCT04421820 | Phase 1/2 | Recruiting | 220 | Primary endpoint not disclosed in English source |
| NCT01415297 | Phase 1 | Completed | 46 | Primary endpoint not disclosed in English source |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Neuroprotective potential of BOLD-100 when utilized in combination with FOLFOX for the treatment of advanced gastrointestinal cancers.
Phase 2; n=109; evaluation: Positive. Reported fields: OIPN incidence = Lower PN incidence was observed across all cohorts relative to benchmarks: mCRC (14% vs 53%), BTC (36% vs 68%), GC (19% vs 63%), and pancreatic cancer (29% vs 38%).
Clinical-stage anticancer agent BOLD-100 demonstrates protective effects against oxaliplatin-induced peripheral neuropathy in an in-vivo rat model
Phase 2; n=not disclosed; evaluation: Positive. Reported fields: Any-grade neuropathy = 14 % ; Any-grade neuropathy = 53 %
BOLD-100-001: A phase II study of BOLD-100 in combination with FOLFOX in advanced mCRC patients that have failed at least two prior lines of therapy
Phase 2; n=38; evaluation: Positive. Reported fields: mPFS = 4.2 Month (95%CI, 3.0)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
NKP-1339 addresses Biliary Tract Neoplasms, Colorectal Cancer, Stomach Cancer. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The MCP screen returned 4 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2022-09-06 | Bold Therapeutics auquired BOLD-100 from Intezyne Technologies | Phase 2 | Financial terms not disclosed |
| 2020-05-29 | Bold Therapeutics and Hana Pharm Execute Option Agreement for Exclusive Development and Commercialization Rights to BOLD-100 in South Korea | Phase 1 | Financial terms not disclosed |
| 2020-05-27 | Bold Therapeutics Executes Option Agreement for Exclusive Development and Commercialization Rights to BOLD-100 in South Korea | Phase 1 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Use of sodium trans-[tetrachloridobis(1h-indazole)ruthenate(III)] to ameliorate proteasome inhibitor resistance”. The milestone feed surfaced a patent-application signal described as “Use of sodium trans-[tetrachloridobis(1h-indazole)ruthenate(III)] for treating cancers”. The milestone feed surfaced a patent-application signal described as “Combined use of sodium trans-[tetrachloridobis(1h-indazole)ruthenate(III)] and etomoxir for treating cancers”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.
7. Principal risks and diligence gates
- Therapeutic index and off-target toxicity
- Resistance biology and biomarker-defined patient selection
- Differentiation from established and emerging standards
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 2026-09-11. Counts and status fields may change as source records update.
